ArticlePakistan journal of medical sciences2025
Clinical efficacy and safety of sintilimab injection plus chemotherapy in patients with stage IB-IIIB non-small cell lung cancer.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Construction of a ubiquitination-related gene signature to predict prognosis and treatment response in lung adenocarcinoma.Pakistan journal of medical sciences · 2026Article
- Efficacy and safety of sintilimab combined with histology-specific chemotherapy in advanced NSCLC: a real-world retrospective study.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the clinical efficacy of sintilimab injection and chemotherapy as neoadjuvant therapy for stage IB-IIIB non-small cell lung cancer(NSCLC), and evaluate its clinical safety. Methods: A retrospective analysis was conducted on the clinical data of patients with stage IB-IIIB NSCLC who underwent neoadjuvant treatment before surgery at Affiliated Hospital of Hebei University, between June 2021 to August 2023. Eighty patients were divided into an observation group(n = 40) and a control group(n = 40) according to their treatment regimens. The control group was administered albumin-bound paclitaxel plus cisplatin, while the observation group received sintilimab injection in addition to the exact treatment provided for the control group. The clinical efficacy, tumor marker levels, immune function, and quality of life were compared between the two groups. Results: After treatment, the overall response rate in the observation group was 85.00%, significantly higher than 65.00% in the control group(P< 0.05). The overall pathological response rate in the observation group was 77.5%, significantly higher than 42.5% in the control group (P< 0.05).During treatment, adverse reactions were observed in both groups. Yet, there was no statistically significant difference in the incidence of adverse drug reactions between the two groups (P > 0.05). Conclusion: The combination therapy of sintilimab injection, albumin-bound paclitaxel, and cisplatin for stage IB-IIIB NSCLC can effectively reduce tumor marker levels, improve immune function, demonstrating favorable clinical and pathological efficacy without increasing the incidence of adverse drug reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.